1-(aminooxy)-2-hydroxy-3-tert-butylaminopropane | 137434-91-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-(aminooxy)-2-hydroxy-3-tert-butylaminopropane
• 英文别名: 3-(aminooxy)-N-tert-butyl-2-hydroxypropanamine；1-aminooxy-3-[(1,1-dimethyl-ethyl)-amino]-2-hydroxy-propane；O-(2-hydroxy-3-tert-butylamino-propyl)-hydroxylamine；1-aminooxy-2-hydroxy-3-[(1,1-dimethylethyl)amino]-propane；1-(Aminooxy)-3-(tert-butylamino)propan-2-ol；1-aminooxy-3-(tert-butylamino)propan-2-ol
• CAS: 137434-91-4
• 化学式: C₇H₁₈N₂O₂
• 分子量: 162.232
• InChiKey: FWJGBYCRQUPGEP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  67.5
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(aminooxy)-2-hydroxy-3-tert-butylaminopropane 、 acetylclonidine 以 乙醇 为溶剂， 反应 48.0h， 以63%的产率得到3,5-dichloro-4-(2-imidazolidinylideneamino)acetophenone O-<3-(tert-butylamino)-2-hydroxypropyl>oxime
  参考文献：
  名称：

  含有β-封端侧链的新咪唑烷衍生物的合成和抗高血压活性。

  摘要：

  描述了新的苯基咪唑烷衍生物（3-6）1的合成，所述苯基咪唑烷衍生物含有连接至芳族环或咪唑烷环的丙醇胺肟或氧丙醇胺部分。对这些化合物在α-胰凝乳蛋白酶诱导的兔高眼压中潜在的眼抗高血压活性进行了评估。这些化合物代表一系列独特的有效的眼用降压药，尽管它们具有β受体阻滞剂和咪唑烷衍生物的结构特征，但它们却显示出弱的α和β肾上腺素能激动剂和拮抗剂活性。这些发现在青光眼的医学管理中可能具有重要的治疗重要性。

  DOI：

  10.1021/jm00115a008
• 作为产物：
  描述：

  N-(3-tert-Butylamino-2-hydroxy-propoxy)-acetimidic acid ethyl ester 在 盐酸 作用下， 生成 1-(aminooxy)-2-hydroxy-3-tert-butylaminopropane
  参考文献：
  名称：

  DE2651083

  摘要：

  公开号：

文献信息

• Activation of carbonic anhydrases from human brain by amino alcohol oxime ethers: towards human carbonic anhydrase VII selective activators
  作者：Alessio Nocentini、Doretta Cuffaro、Lidia Ciccone、Elisabetta Orlandini、Susanna Nencetti、Elisa Nuti、Armando Rossello、Claudiu T. Supuran

  DOI：10.1080/14756366.2020.1838501

  日期：2021.1.1

  Furthermore, a multitude of selective hCA VII activators were identified. As hCA VII is one of the key isoforms involved in brain metabolism and other brain functions, the identified potent and selective hCA VII activators may be considered of interest for investigations of various therapeutic applications or as lead compounds in search of even more potent and selective CA activators.

  摘要 描述了一系列基于肟醚的氨基醇对人脑中表达的四种人（h）CA异构体hCA I，II，IV和VII的合成和碳酸酐酶（CA; EC 4.2.1.1）的激活作用。大多数研究的氨基醇衍生物均以K A诱导了被测CA的一致活化。范围从低微摩尔到中等纳摩尔。具体而言，当涉及中枢神经系统（CNS）疾病时，hCA II和VII是假定的主要CA靶标，这些肟醚衍生物可最有效地激活它们。此外，鉴定了多种选择性hCA VII活化剂。由于hCA VII是参与大脑代谢和其他脑功能的关键同工型之一，因此，已鉴定出的有效和选择性hCA VII激活剂可能被认为是研究各种治疗应用或作为寻找更有效和选择性CA的先导化合物感兴趣激活剂。
• New chiral and isomeric cyclopropyl ketoxime propanolamine derivatives with potent .beta.-adrenergic blocking properties
  作者：Mohamed Bouzoubaa、Gerard Leclerc、Suman Rakhit、Guy Andermann

  DOI：10.1021/jm00145a008

  日期：1985.7

  The synthesis of R-(+) and S-(-) isomers of O-[3-tert-butylamino)-2-hydroxypropyl] cyclopropyl methyl ketone oxime (falintolol) is described. The syn and anti isomers of falintolol were obtained in two different ways from cyclopropyl methyl ketoxime or from falintolol. For comparison purposes, the enantiomers of the dicyclopropyl ketone oxime derivatives were also prepared. Structure-activity relationships

  描述了O- [3-叔丁基氨基）-2-羟丙基]环丙基甲基酮肟（氟林醇）的R-（+）和S-（-）异构体的合成。法林特洛的顺式和反式异构体是从环丙基甲基酮肟或法林特洛以两种不同方式获得的。为了比较，还制备了二环丙基酮肟衍生物的对映体。描述了构效关系。
• Anti-ischaemic hydroxylamine derivatives and pharmaceutical compositions
  申请人：Biorex Research & Development Co.

  公开号：US06002002A1

  公开（公告）日：1999-12-14

  The present invention provides novel hydroxylamine derivatives represented by the general formula: wherein: X is O, --NH, or a group of formula NR', wherein R and R' are independently selected from alkyl, cycloalkyl, phenylalkyl, phenyl optionally substituted with halo, haloalkyl, alkyl, alkoxy or nitro; and a N-containing heterocyclic ring; R.sup.1 is H or alkanoyl, R.sup.2 is H or hydroxy optionally acylated with alkanoyl, and R.sup.3 is a group of the formula --NR.sup.4 R.sup.5 wherein R.sup.4 and R.sup.5 are independently selected from H, alkyl, and a group of the formula --CO--NH--R wherein R is as defined above, or wherein R.sup.4 and R.sup.5 when taken together form a 5- to 7-membered heterocyclic ring which may optionally contain one additional hetero atom selected from nitrogen, oxygen and sulfur and which is optionally substituted with alkyl or phenylalkyl. Also provided are pharmaceutically acceptable acid addition salts of the compounds defined above, as well as pharmaceutical compositions containing the compounds or their acid addition salts as active ingredients. The compounds of the invention have been shown to have anti-ischemic effects.

  本发明提供了一种由通式表示的新型羟胺衍生物：其中：X为O、-NH，或者是一个由通式NR'表示的基团，其中R和R'分别独立地选自烷基、环烷基、苯基烷基、苯基（可选择地取代卤素、卤代烷基、烷基、烷氧基或硝基）和含氮杂环；R^1为H或烷酰基，R^2为H或羟基（可选择地酰化为烷酰基），R^3为由通式-NR^4R^5表示的基团，其中R^4和R^5独立地选自H、烷基，以及由通式-CO-NH-R表示的基团，其中R如上所定义，或者当R^4和R^5结合在一起形成一个5-至7-成员的杂环，该杂环可选择地含有一个额外的氮、氧和硫中选择的杂原子，并且可选择地取代为烷基或苯基烷基。此外，还提供了上述化合物的药学上可接受的酸盐，以及含有这些化合物或它们的酸盐盐作为活性成分的药物组合物。该发明的化合物已被证明具有抗缺血作用。
• Use of hydroxylamine derivatives, and method and preparations for increasing the tolerance of field crops against weather stresses
  申请人：——

  公开号：US20010051630A1

  公开（公告）日：2001-12-13

  This invention relates to the use of hydroxylamine derivatives of general formula (I), wherein R 1 represents phenyl, N-heteroaryl, S-heteroaryl or a naphthyl group any of which may be unsubstituted or substituted, an unsubstituted or substituted phenylamino or alkylamino or lower alkoxy; X represents halo, amino or an unsubstituted or substituted phenylamino group, or amino substituted with one or two lower alkyl or a hydroxy group, provided that if R 1 represents unsubstituted or substituted phenylamino, alkylamino or lower alkoxy, then X is not halo; Y represents hydrogen, hydroxy or alkanoyloxy, with the proviso that simultaneously R 1 may not represent phenyl, halophenyl, alkoxyphenyl, N-heteroaryl or naphthyl, X may not represent halo, hydroxy or amino and Y may not represent hydrogen or hydroxy; R 2 and R 3 , independently from each other, represent hydrogen or lower alkyl group, provided that R 2 and R 3 are not hydrogen simultaneously, or R 2 and R 3 along with the adjacent nitrogen atom form a 5- to 7-membered saturated hetero ring, to increase the tolerance of cultivated plants against weather condition stresses, such as cold, frost and drought.

  本发明涉及使用羟胺衍生物的一般式(I)，其中R1代表苯基、N-杂环基、S-杂环基或萘基，其中任何一个可能未取代或取代，未取代或取代的苯氨基或烷基氨基或较低的烷氧基；X代表卤素、氨基或未取代或取代的苯氨基基团，或取代一或两个较低的烷基或羟基的氨基，但如果R1代表未取代或取代的苯氨基、烷基氨基或较低烷氧基，则X不是卤素；Y代表氢、羟基或脂肪酰氧基，但同时R1不能表示苯基、卤苯基、烷氧基苯基、N-杂环基或萘基，X不能表示卤素、羟基或氨基，Y不能表示氢或羟基；R2和R3相互独立地代表氢或较低的烷基，但要求R2和R3不能同时为氢，或者R2和R3与相邻的氮原子一起形成5-至7-成员的饱和杂环，以提高栽培植物对天气条件胁迫，如寒冷、霜冻和干旱的耐受性。
• Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof
  申请人：Biorex Research & Development Co.

  公开号：US20040019103A1

  公开（公告）日：2004-01-29

  A method of increasing expression of a molecular chaperon by a cell and/or enhancing the activity of a molecular chaperon in cells is provided. The method comprises treating a cell that is exposed to a physiological stress which induces expression of a molecular chaperon by the cell with an effective amount of a certain hydroxylamine derivative to increase the stress. Alternatively, an hydroxylamine derivative can be administrated to a cell before it is exposed to a physiological stress which induces expression of a molecular chaperon by the cell. Preferably, the cell to which an hydroxylamine derivative is administered is an eukaryotic cell. The hydroxylamine derivative corresponds to the formulae (I) or (II). The invention also provides novel hydroxylamine derivatives falling within the scope of the formulae (I) and (II) as well as pharmaceutical and/or cosmetical compositions comprising the said compounds.

  提供了一种通过细胞增加分子伴侣的表达和/或增强细胞中分子伴侣活性的方法。该方法包括将受到诱导细胞表达分子伴侣的生理应激暴露的细胞，用一定量的某种羟胺衍生物进行处理，以增加应激。或者，在细胞暴露于诱导细胞表达分子伴侣的生理应激之前，可以向细胞中给予羟胺衍生物。最好给予羟胺衍生物的细胞是真核细胞。羟胺衍生物对应于式(I)或(II)。该发明还提供了落在式(I)和(II)范围内的新羟胺衍生物，以及包含所述化合物的药物和/或化妆品组合物。